D. Gilliland

Molecular Biology · 2002–2013

A researcher in the Science corpus: 13 papers; trusts 1 researcher and is trusted by 4 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 104 citations into it; #12,529 of 17,773 by trust here, #3,584 by citations

Whom D. Gilliland trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Brian J. Druker

Who trusts D. Gilliland overall

1. M. Greaves
2. Daniel G. Tenen

Papers from D. Gilliland's perspective

Ordered by how strongly the researchers D. Gilliland trusts endorse each paper. Same corpus, a different order for every researcher.

1. Stem cells, cancer, and cancer stem cells (Nature)
2. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (New England Journal of Medicine)
3. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. (Science)
4. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. (New England Journal of Medicine)
5. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. (Blood)
6. The Hallmarks of Cancer Review
7. MAML1, a human homologue of Drosophila Mastermind, is a transcriptional co-activator for NOTCH receptors (Nature Genetics)
8. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who… (Blood)
9. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. (Cell)
10. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. (Blood)

Their papers

• Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth (2009) — 782 citations
• FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. (2007) — 1,101 citations
• Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 (2009) — 3,376 citations
• Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. (2013) — 615 citations
• Leukaemia stem cells and the evolution of cancer-stem-cell research (2005) — 654 citations
• Core-binding factors in haematopoiesis and leukaemia (2002) — 620 citations
• Direct inhibition of the NOTCH transcription factor complex (2009) — 758 citations
• Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. (2005) — 3,130 citations
• Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. (2005) — 1,536 citations
• Drug therapy for acute myeloid leukemia. (2005) — 695 citations
• A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. (2003) — 1,745 citations
• Genetics of myeloid leukemias. (2003) — 609 citations
• The roles of FLT3 in hematopoiesis and leukemia. (2002) — 1,621 citations